KAND567

DRUG3 trials

Sponsors

Novakand Pharma AB

Conditions

Covid19Epithelial Ovarian CancerFallopian Tube CancerHealthyPeritoneal Cancer

Phase 1

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

CompletedNCT06030375

Novakand Pharma ABHealthy

Start: 2020-02-17End: 2020-04-27Updated: 2023-09-11

A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT06087289

Novakand Pharma ABEpithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Start: 2023-04-26End: 2025-04-03Updated: 2025-06-08

Phase 2

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

TerminatedNCT06012565

Novakand Pharma ABCovid19

Start: 2020-10-11End: 2021-08-07Updated: 2023-08-25